A new trading day began on Monday, with ARS Pharmaceuticals Inc (NASDAQ: SPRY) stock price down -5.86% from the previous day of trading, before settling in for the closing price of $9.90. SPRY’s price has ranged from $2.55 to $11.90 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company slipped by -34.76% over the past five years. Meanwhile, its annual earnings per share averaged -1.32%. With a float of $47.57 million, this company’s outstanding shares have now reached $96.41 million.
Let’s look at the performance matrix of the company that is accounted for 26 employees.
ARS Pharmaceuticals Inc (SPRY) Insider Updates
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of ARS Pharmaceuticals Inc is 50.90%, while institutional ownership is 35.22%. The most recent insider transaction that took place on Jul 16 ’24, was worth 1,140,295. In this transaction CHIEF MEDICAL OFFICER of this company sold 100,000 shares at a rate of $11.40, taking the stock ownership to the 1,547,447 shares. Before that another transaction happened on Jul 16 ’24, when Company’s PRESIDENT AND CEO sold 100,000 for $11.40, making the entire transaction worth $1,140,295. This insider now owns 1,547,447 shares in total.
ARS Pharmaceuticals Inc (SPRY) Performance Highlights and Predictions
In its latest quarterly report, released on 3/31/2024, the company reported earnings of -0.18 per share, which was $0.1 lower than the consensus estimate of $0.26. In terms of return on equity, this company recorded -19.55% in contrast with 50.0% return on Investment (trailing twelve months). Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.16 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -1.32% per share during the next fiscal year.
ARS Pharmaceuticals Inc (NASDAQ: SPRY) Trading Performance Indicators
Here are ARS Pharmaceuticals Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 60.84. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 90310.80.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.52, a number that is poised to hit -0.11 in the next quarter and is forecasted to reach -0.55 in one year’s time.
Technical Analysis of ARS Pharmaceuticals Inc (SPRY)
ARS Pharmaceuticals Inc (NASDAQ: SPRY) saw its 5-day average volume 0.54 million, a negative change from its year-to-date volume of 0.6 million. As of the previous 9 days, the stock’s Stochastic %D was 19.35%. Additionally, its Average True Range was 0.61.
During the past 100 days, ARS Pharmaceuticals Inc’s (SPRY) raw stochastic average was set at 40.69%, which indicates a significant increase from 15.27% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 59.54% in the past 14 days, which was higher than the 56.17% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $9.50, while its 200-day Moving Average is $7.51. Nevertheless, the first resistance level for the watch stands at $9.56 in the near term. At $9.81, the stock is likely to face the second major resistance level. The third major resistance level sits at $10.14. If the price goes on to break the first support level at $8.99, it is likely to go to the next support level at $8.66. Assuming the price breaks the second support level, the third support level stands at $8.42.
ARS Pharmaceuticals Inc (NASDAQ: SPRY) Key Stats
With a market capitalization of 903.11 million, the company has a total of 96,895K Shares Outstanding. Currently, annual sales are 30 K while annual income is -54,370 K. The company’s previous quarter sales were 0 K while its latest quarter income was -10,290 K.
